RxDoctor Payments Data

David Rider, MD

Family Medicine · Seguin, TXNPI 1326202185

Payments from drug & device makers

$1,491in general payments, 2019–2025

Across 28 payments — averaging $53.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$181
  • Lilly USA, LLC$140
  • Aerin Medical Inc.$135
  • Novo Nordisk$121
  • AbbVie$112
  • Merck$111
  • plus $690 from 12 others

What the payments were for

  • Food & beverage$1,491100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,491 in reported general payments places this provider in the 65th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$145,365
Medicare patients
382
Services billed
2,425

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide196$197,490
EliquisApixaban90$107,534
TrulicityDulaglutide56$77,954
JardianceEmpagliflozin64$54,375
MounjaroTirzepatide25$26,947
Trelegy ElliptaFluticasone/Umeclidin/Vilanter38$25,603
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog30$25,046
FarxigaDapagliflozin Propanediol36$23,832
XareltoRivaroxaban19$19,058
MyrbetriqMirabegron30$16,522
Tresiba Flextouch U-200Insulin Degludec17$10,717
ShingrixVaricella-Zoster Ge/As01b/Pf42$9,435
Levothyroxine Sodium622$8,163
Tresiba Flextouch U-100Insulin Degludec14$7,933
Celecoxib256$7,358

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$121$197,490196 claims
Lilly USA, LLCTrulicity, Mounjaro$140$104,90081 claims
AstraZenecaFarxiga$71$23,83236 claims
Johnson & JohnsonXarelto$51$19,05819 claims
AbbVieSynthroid$112$1,74042 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Seguin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →